关键词： Merck 神经系统科学项目 Cerecor
2013年4月22日讯 /生物谷BIOON/ --位于美国城市巴尔的摩的Cerecor生物技术公司已经从Merck公司获取了两项关于神经系统科学的研究项目。这两项项目分别是对MK-0657和catechol-O-methyltransferase (COMT)抑制剂两种新型药物的研究。Cerecor称获得这两种药物的研发销售权利有利于公司在神经科学领域的深入研究。（生物谷Bioon.com）
详细英文报道：
Cerecor, a Baltimore-based biotech focused on neuroscience, has picked up two CNS programs from the U.S. drug giant Merck ($MRK). The biotech outfit acquired exclusive global rights to MK-0657, an NR2B antagonist, as well as similar rights to catechol-O-methyltransferase (COMT) inhibitors from Merck. Merck initially studied MRK-0657 for Parkinson's disease, yet Cerecor says that the compound impacts a pathway involving depression and other disorders. The COMT inhibitors also offer the potential to treat multiple neuroscience targets.
(责任编辑：lili.zhao)
